Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

SpringWorks Therapeutics stock

SWTX
US85205L1070
A2PRLN

Price

30.62
Today +/-
+0.45
Today %
+1.61 %
P

SpringWorks Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the SpringWorks Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the SpringWorks Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the SpringWorks Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze SpringWorks Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

SpringWorks Therapeutics Stock Price History

DateSpringWorks Therapeutics Price
11/1/202430.62 undefined
10/31/202430.13 undefined
10/30/202430.48 undefined
10/29/202430.13 undefined
10/28/202429.89 undefined
10/25/202429.31 undefined
10/24/202429.11 undefined
10/23/202428.61 undefined
10/22/202429.80 undefined
10/21/202430.49 undefined
10/18/202430.97 undefined
10/17/202430.78 undefined
10/16/202430.12 undefined
10/15/202430.50 undefined
10/14/202430.45 undefined
10/11/202430.67 undefined
10/10/202430.35 undefined
10/9/202431.00 undefined
10/8/202432.41 undefined
10/7/202432.27 undefined

SpringWorks Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SpringWorks Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SpringWorks Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SpringWorks Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SpringWorks Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SpringWorks Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SpringWorks Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SpringWorks Therapeutics’s growth potential.

SpringWorks Therapeutics Revenue, EBIT and net profit per share

DateSpringWorks Therapeutics RevenueSpringWorks Therapeutics EBITSpringWorks Therapeutics Net Income
2028e2.05 B undefined-112.51 M undefined-90.91 M undefined
2027e1.2 B undefined166.94 M undefined374.23 M undefined
2026e531.1 M undefined-116.49 M undefined-113.38 M undefined
2025e388.27 M undefined-162.04 M undefined-162.42 M undefined
2024e196.02 M undefined-274.94 M undefined-251.37 M undefined
20235.45 M undefined-343.01 M undefined-325.1 M undefined
20220 undefined-280.67 M undefined-277.42 M undefined
20210 undefined-173.47 M undefined-173.91 M undefined
202035 M undefined-46.32 M undefined-45.57 M undefined
20190 undefined-59.24 M undefined-50.58 M undefined
20180 undefined-18.49 M undefined-17.81 M undefined
20170 undefined-4.66 M undefined-4.64 M undefined

SpringWorks Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e
0000.04000.010.20.390.531.22.05
-------3,820.0097.9636.86125.8071.06
------100.00-----
000000500000
-4-18-59-46-173-280-343-274-162-116166-112
----131.43---6,860.00-139.80-41.75-21.8513.84-5.46
-4-17-50-45-173-277-325-251-162-113374-90
-325.00194.12-10.00284.4460.1217.33-22.77-35.46-30.25-430.97-124.06
41.8841.884343.348.553.2963.1200000
------------
Details

Keystats

ⓘ

Revenue and Growth

The SpringWorks Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the SpringWorks Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2017201820192020202120222023
             
10.345.6327.7508.5373.5592.2479.2
0000005.93
0000000
0000003.1
0.31.43.74.99.47.512.68
10.647331.4513.4382.9599.7500.91
00.30.834.218.324.09
00157.262.19185.34
0000000
00000011.2
0000000
011.72.63.33.24.25
01.33.562.869.630.5224.88
10.648.3334.9576.2452.5630.2725.79
             
14.664.900000.01
000.40.680.721.131.52
-4.6-22.5-73-118.6-292.5-569.9-895.03
0000-0.3-0.81.19
0000000
1043.5322.1557422.4559.5630.36
0.30.82.71.43.487.4
0.42.6916.326.539.766.63
00.30.4003.34.14
0000000
0001.41.160.480
0.73.712.119.131.0651.4878.17
0000000
0000000
01.20.81.50.12121.4
01.20.81.50.12121.4
0.74.912.920.631.1672.4899.57
10.748.4335577.6453.56631.98729.93
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of SpringWorks Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand SpringWorks Therapeutics's financial health and stability.

Assets

SpringWorks Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that SpringWorks Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of SpringWorks Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into SpringWorks Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-4-17-58-45-173-277-325
0000001,000
0000000
02415380
2282178149195
0000000
0000000
-2-14-47-32-127-161-222
0000-2-10-7
00-4-41883-21534
00-3-41885-20542
0000000
0000000
12503332701340296
12503332701340296
-------
0000000
1035282-180-43-36108
-2.28-14.46-48.11-32.83-129.9-171.76-230.18
0000000

SpringWorks Therapeutics stock margins

The SpringWorks Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SpringWorks Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SpringWorks Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SpringWorks Therapeutics's sales revenue. A higher gross margin percentage indicates that the SpringWorks Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SpringWorks Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SpringWorks Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SpringWorks Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SpringWorks Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SpringWorks Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SpringWorks Therapeutics Margin History

SpringWorks Therapeutics Gross marginSpringWorks Therapeutics Profit marginSpringWorks Therapeutics EBIT marginSpringWorks Therapeutics Profit margin
2028e92.25 %-5.49 %-4.43 %
2027e92.25 %13.92 %31.21 %
2026e92.25 %-21.93 %-21.35 %
2025e92.25 %-41.73 %-41.83 %
2024e92.25 %-140.26 %-128.24 %
202392.25 %-6,297.28 %-5,968.5 %
202292.25 %0 %0 %
202192.25 %0 %0 %
202092.25 %-132.34 %-130.2 %
201992.25 %0 %0 %
201892.25 %0 %0 %
201792.25 %0 %0 %

SpringWorks Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The SpringWorks Therapeutics earnings per share therefore indicates how much revenue SpringWorks Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SpringWorks Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SpringWorks Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SpringWorks Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SpringWorks Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SpringWorks Therapeutics Revenue, EBIT and net profit per share

DateSpringWorks Therapeutics Sales per ShareSpringWorks Therapeutics EBIT per shareSpringWorks Therapeutics Earnings per Share
2028e27.62 undefined0 undefined-1.22 undefined
2027e16.14 undefined0 undefined5.04 undefined
2026e7.15 undefined0 undefined-1.53 undefined
2025e5.23 undefined0 undefined-2.19 undefined
2024e2.64 undefined0 undefined-3.38 undefined
20230.09 undefined-5.43 undefined-5.15 undefined
20220 undefined-5.27 undefined-5.21 undefined
20210 undefined-3.58 undefined-3.59 undefined
20200.81 undefined-1.07 undefined-1.05 undefined
20190 undefined-1.38 undefined-1.18 undefined
20180 undefined-0.44 undefined-0.43 undefined
20170 undefined-0.11 undefined-0.11 undefined

SpringWorks Therapeutics business model

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative drugs for rare and hard-to-treat diseases. The company was founded by Pfizer Inc. in 2017 and is headquartered in Stamford, Connecticut, USA. Since then, it has become one of the leading companies in the industry and works closely with scientists, doctors, and patients to develop better therapies for rare diseases. The business model of SpringWorks Therapeutics Inc is based on identifying and developing drugs for chronic and severe diseases with currently no satisfactory treatment options. The company places great emphasis on the use of new technologies and scientific knowledge to maximize the effectiveness and safety of its drugs. At the same time, it strives to advance product development as quickly and efficiently as possible in order to offer patients better treatment options as soon as possible. An important part of SpringWorks Therapeutics Inc's business model is partnerships and collaborations with other companies and institutions. The company works closely with other biopharmaceutical and biotechnology companies to accelerate its development plans and maximize the potential of its drugs. It also maintains close relationships with research institutes, such as the National Institutes of Health (NIH), to gain the latest scientific knowledge and translate it into new therapies. SpringWorks Therapeutics Inc specializes in the development of drugs for rare and hard-to-treat diseases. The company focuses on four main areas: oncology, neurology, hematology, and pediatrics. In each of these areas, the company has a number of promising programs and products in development. In the oncology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare and hard-to-treat types of cancer. An important program in this area is the development program for Nirogacestat, a gamma-secretase inhibitor. This program has the potential to provide a new treatment option for patients with T-cell lymphoblastic lymphoma (T-ALL) and Alport syndrome. In the neurology field, SpringWorks Therapeutics Inc develops therapies for patients with rare neurological diseases that currently have no satisfactory treatment options. An important focus in this area is the development program for Mirdametinib, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with neurofibromatosis type 1 (NF1). In the hematology field, SpringWorks Therapeutics Inc focuses on developing therapies for patients with rare hematological diseases such as myelofibrosis, chronic myeloid leukemia (CML), and acute myeloid leukemia (AML). An important focus in this area is the development program for Senexin A, an inhibitor of protein methyltransferases. This program has the potential to provide a new therapy for patients with myelofibrosis. In the pediatrics field, SpringWorks Therapeutics Inc develops therapies for children with rare and severe diseases such as nephrotic syndrome and epilepsy. An important program in this area is the development program for PD-0325901, a MEK1/2 inhibitor. This program has the potential to offer a new treatment for patients with nephrotic syndrome. Overall, SpringWorks Therapeutics Inc has an impressive pipeline of promising development programs that have the potential to improve the lives of patients with rare and hard-to-treat diseases. Through its close collaboration with other companies, research institutes, and patient organizations, the company is able to effectively and efficiently implement its development plans and thus create better treatment options for patients around the world. SpringWorks Therapeutics is one of the most popular companies on Eulerpool.com.

SpringWorks Therapeutics SWOT Analysis

Strengths

SpringWorks Therapeutics Inc has a robust portfolio of innovative drugs and therapies. This enables them to address various medical conditions and provides a competitive edge in the market.

The company has a highly skilled and experienced team of professionals who possess deep expertise in areas crucial to their operations. This enhances their ability to develop and commercialize effective treatment solutions.

Weaknesses

SpringWorks Therapeutics Inc faces challenges in expanding its market presence, especially in highly competitive markets. This may limit their ability to reach a wider customer base and gain market share.

The company relies heavily on partnerships for key aspects of its operations, such as research collaborations and distribution agreements. Any strain on these partnerships or potential disruptions could impact their growth and development strategies.

Opportunities

Advancements in medical technology and a growing demand for innovative therapies present opportunities for SpringWorks Therapeutics Inc. They can capitalize on these trends by developing new and improved treatment options.

The company has the potential to expand its operations into new markets globally, thereby increasing its customer base and revenue streams. This can be achieved through strategic partnerships, acquisitions, or entering untapped geographical regions.

Threats

SpringWorks Therapeutics Inc operates in a highly regulated industry, and any changes in regulations, compliance requirements, or delays in obtaining necessary approvals can pose threats to their product development and commercialization efforts.

The company faces fierce competition from both established pharmaceutical companies and emerging biotechnology firms. Rivalry in the market may result in pricing pressures, loss of market share, and difficulties in differentiating their offerings.

SpringWorks Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

SpringWorks Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

SpringWorks Therapeutics shares outstanding

The number of shares was SpringWorks Therapeutics in 2023 — This indicates how many shares 63.124 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SpringWorks Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SpringWorks Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SpringWorks Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SpringWorks Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for SpringWorks Therapeutics.

SpringWorks Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-1.14 -0.54  (52.52 %)2024 Q2
3/31/2024-1.2 -1.18  (1.26 %)2024 Q1
12/31/2023-1.27 -1.45  (-14.6 %)2023 Q4
9/30/2023-1.36 -1.27  (6.38 %)2023 Q3
6/30/2023-1.29 -1.25  (2.89 %)2023 Q2
3/31/2023-1.27 -1.18  (6.85 %)2023 Q1
12/31/2022-1.25 -1.17  (6.11 %)2022 Q4
9/30/2022-1.34 -1.37  (-1.76 %)2022 Q3
6/30/2022-1.23 -1.41  (-14.88 %)2022 Q2
3/31/2022-1.04 -1.26  (-20.71 %)2022 Q1
1
2

Eulerpool ESG Scorecard© for the SpringWorks Therapeutics stock

Eulerpool World ESG Rating (EESG©)

35/ 100

🌱 Environment

37

👫 Social

47

🏛️ Governance

22

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

SpringWorks Therapeutics shareholders

%
Name
Stocks
Change
Date
14.96215 % Fidelity Management & Research Company LLC11,112,39144,3656/30/2024
8.79528 % The Vanguard Group, Inc.6,532,25613,1336/30/2024
6.74272 % BlackRock Institutional Trust Company, N.A.5,007,819137,3526/30/2024
4.98182 % Deep Track Capital LP3,700,000220,1476/30/2024
4.74405 % T. Rowe Price Associates, Inc.3,523,405-508,9246/30/2024
4.60690 % Boxer Capital, L.L.C.3,421,541010/10/2024
4.15625 % State Street Global Advisors (US)3,086,845125,2216/30/2024
3.50145 % Maverick Capital, Ltd.2,600,524691,8946/30/2024
3.14140 % Marshall Wace LLP2,333,117-633,5056/30/2024
2.79247 % Lord, Abbett & Co. LLC2,073,970-243,8406/30/2024
1
2
3
4
5
...
10

SpringWorks Therapeutics Executives and Management Board

Mr. Saqib Islam(53)
SpringWorks Therapeutics Chief Executive Officer, Director
Compensation 15.3 M
Dr. Badreddin Edris(36)
SpringWorks Therapeutics Chief Operating Officer
Compensation 5.68 M
Mr. Bhavesh Ashar(57)
SpringWorks Therapeutics Chief Commercial Officer
Compensation 4.94 M
Mr. Francis Perier(63)
SpringWorks Therapeutics Chief Financial Officer
Compensation 4.08 M
Mr. Herschel Weinstein(67)
SpringWorks Therapeutics General Counsel, Secretary
Compensation 2.8 M
1
2
3

SpringWorks Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Personalis Stock
Personalis
SupplierCustomer0,790,960,910,830,850,55
Jazz Pharmaceuticals Stock
Jazz Pharmaceuticals
SupplierCustomer0,410,870,58-0,420,210,58
Pfizer Stock
Pfizer
SupplierCustomer0,350,83-0,090,18-0,63-0,12
BeiGene Stock
BeiGene
SupplierCustomer0,330,750,700,770,690,71
Johnson & Johnson Stock
Johnson & Johnson
SupplierCustomer0,32-0,18-0,75-0,82-0,460,20
Seagen Stock
Seagen
SupplierCustomer0,310,040,520,530,510,09
Precision BioSciences Stock
Precision BioSciences
SupplierCustomer0,270,870,850,800,810,75
GlaxoSmithKline Stock
GlaxoSmithKline
SupplierCustomer0,260,59-0,69-0,68-0,74-0,65
AbbVie Stock
AbbVie
SupplierCustomer0,240,62-0,32-0,69-0,73-0,14
Allogene Therapeutics Stock
Allogene Therapeutics
SupplierCustomer0,130,870,760,750,840,09
1

Most common questions regarding SpringWorks Therapeutics

What values and corporate philosophy does SpringWorks Therapeutics represent?

SpringWorks Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for patients with severe rare diseases and cancer. The company's core values include dedication, integrity, and collaboration in their pursuit of discovering novel treatments. With a patient-centric approach, SpringWorks Therapeutics aims to improve the lives of individuals affected by these debilitating conditions. They prioritize scientific excellence and ethical practices to deliver safe and effective therapies. Through strategic partnerships and pioneering research, the company strives to bring hope and transformative solutions to patients in need. SpringWorks Therapeutics Inc is committed to making a lasting impact in the lives of patients and their families.

In which countries and regions is SpringWorks Therapeutics primarily present?

SpringWorks Therapeutics Inc is primarily present in the United States.

What significant milestones has the company SpringWorks Therapeutics achieved?

Some significant milestones achieved by SpringWorks Therapeutics Inc include the approval of their lead product candidate, Nirogacestat, for the treatment of desmoid tumors by the U.S. FDA. The company also received Fast Track and Orphan Drug designations for Nirogacestat, which further highlights its potential in addressing unmet medical needs. Additionally, SpringWorks Therapeutics Inc has successfully initiated multiple clinical trials evaluating various therapies for rare cancers and genetic diseases. These accomplishments demonstrate the company's commitment towards advancing innovative treatments and improving patients' lives.

What is the history and background of the company SpringWorks Therapeutics?

SpringWorks Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing life-changing therapies for patients with severe rare diseases and cancer. Founded in 2017, SpringWorks Therapeutics is committed to delivering innovative treatments by leveraging its strategic collaborations and advanced drug development expertise. With a diverse pipeline of investigational therapies, the company aims to address unmet medical needs and improve patients' lives globally. SpringWorks Therapeutics Inc has made significant progress in its mission to transform the lives of patients through its dedication to scientific excellence and groundbreaking research in the field of precision medicine.

Who are the main competitors of SpringWorks Therapeutics in the market?

The main competitors of SpringWorks Therapeutics Inc in the market include companies like Novartis, Pfizer, and Roche.

In which industries is SpringWorks Therapeutics primarily active?

SpringWorks Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of SpringWorks Therapeutics?

The business model of SpringWorks Therapeutics Inc. is focused on developing and commercializing innovative targeted therapies for patients with severe rare diseases and cancer. The company aims to identify promising drug candidates and advance them through clinical development to address unmet medical needs. SpringWorks Therapeutics Inc. collaborates with both academic institutions and industry partners to leverage its expertise and optimize the development of potential treatments. By utilizing targeted therapies, the company aims to provide effective and personalized solutions for patients, with a focus on improving their overall quality of life.

What is the P/E ratio of SpringWorks Therapeutics 2024?

The SpringWorks Therapeutics P/E ratio is -7.69.

What is the P/S ratio of SpringWorks Therapeutics 2024?

The SpringWorks Therapeutics P/S ratio is 9.86.

What is the Quality Investing of SpringWorks Therapeutics?

The Quality Investing for SpringWorks Therapeutics is 3/10.

What is the revenue of SpringWorks Therapeutics 2024?

The expected SpringWorks Therapeutics revenue is 196.02 M USD.

How high is the profit of SpringWorks Therapeutics 2024?

The expected SpringWorks Therapeutics profit is -251.37 M USD.

What is the business model of SpringWorks Therapeutics

SpringWorks Therapeutics is a biopharmaceutical company focused on developing therapeutics for patients with rare severe diseases. The business model involves developing innovative therapies with high medical necessity and making them accessible to the market. The company specializes in three main areas: oncology, inherited metabolic disorders, and neurological disorders. SpringWorks aims to develop new and effective therapies for each of these diseases. In the oncology sector, SpringWorks utilizes its expertise in drug discovery and development to create innovative cancer therapies. One of the leading products is Nirogacestat, a Notch pathway inhibitor that has the potential to be used against solid tumors that do not respond to other forms of therapy. In the inherited metabolic disorders division, SpringWorks is working on developing therapies for patients with rare diseases such as Niemann-Pick Type C syndrome. The company has partnered with Cydan Development, a company specializing in developing drugs for rare genetic disorders, for this purpose. In the field of neurological disorders, SpringWorks aims to develop therapies for patients with rare genetic diseases such as epilepsy and Huntington's disease. The company has initiated a collaboration with the Hospital for Sick Children in Toronto for this purpose. The company also has an innovative technology called "Biomarker Relocation" which allows for the identification of patients with certain rare diseases that are otherwise difficult to diagnose and treat. The technology is currently a significant component of SpringWorks' research and development efforts. In recent years, the company has raised capital through investments and collaborations for its business model. The funding has been based on venture capital from leading companies including Novartis Venture Fund, Pfizer Ventures, and OrbiMed. SpringWorks' business strategy also includes partnerships with other companies and research institutions. One collaboration, for example, exists with the Memorial Sloan Kettering Cancer Center, a leading institution in cancer research. The vision of SpringWorks is to play a leading role in the development of therapeutics for patients with rare diseases and to meet the medical need in this area. The company strives to improve the lives of patients with rare diseases and provide them with an optimal medication that alleviates their condition and enhances their quality of life. Overall, SpringWorks is an emerging player in the biotech industry, developing innovative therapeutics to address the needs of patients with rare diseases. With a presence in multiple medical specialties and a strong financing base, the company is poised to secure a position at the forefront of the biotech industry.

What is the SpringWorks Therapeutics dividend?

SpringWorks Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does SpringWorks Therapeutics pay dividends?

The dividend cannot currently be calculated for SpringWorks Therapeutics or the company does not pay out a dividend.

What is the SpringWorks Therapeutics ISIN?

The ISIN of SpringWorks Therapeutics is US85205L1070.

What is the SpringWorks Therapeutics WKN?

The WKN of SpringWorks Therapeutics is A2PRLN.

What is the SpringWorks Therapeutics ticker?

The ticker of SpringWorks Therapeutics is SWTX.

How much dividend does SpringWorks Therapeutics pay?

Over the past 12 months, SpringWorks Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SpringWorks Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of SpringWorks Therapeutics?

The current dividend yield of SpringWorks Therapeutics is .

When does SpringWorks Therapeutics pay dividends?

SpringWorks Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SpringWorks Therapeutics?

SpringWorks Therapeutics paid dividends every year for the past 0 years.

What is the dividend of SpringWorks Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is SpringWorks Therapeutics located?

SpringWorks Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von SpringWorks Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SpringWorks Therapeutics from 11/3/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/3/2024.

When did SpringWorks Therapeutics pay the last dividend?

The last dividend was paid out on 11/3/2024.

What was the dividend of SpringWorks Therapeutics in the year 2023?

In the year 2023, SpringWorks Therapeutics distributed 0 USD as dividends.

In which currency does SpringWorks Therapeutics pay out the dividend?

The dividends of SpringWorks Therapeutics are distributed in USD.

All fundamentals about SpringWorks Therapeutics

Our stock analysis for SpringWorks Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SpringWorks Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.